Tirzepatide Peptide

Tirzepatide Dosage: The Approved Titration Schedule and Clinical-Trial Protocols

The short version

Tirzepatide is an FDA-approved prescription medicine given as a once-weekly subcutaneous (under-the-skin) injection. The starting dose, per the FDA label, is 2.5 mg once weekly for four weeks, then escalated in steps to higher maintenance doses. In the SURPASS and SURMOUNT clinical trials, the three maintenance doses studied were 5 mg, 10 mg, and 15 mg once weekly, each reached after a stepwise escalation phase. The half-life is approximately five days — the albumin-binding fatty-diacid modification on the peptide structure is what makes once-weekly dosing workable.

This page covers the titration schedule as documented in the label and trials, the half-life pharmacokinetics, the injection route, and what the clinical trials found at each dose. No dosing recommendation is made here. Every figure is attributed to a labeled or trial-documented source.

Tirzepatide dosage: the approved titration ladder

The FDA prescribing information for tirzepatide documents the following titration schedule for type 2 diabetes: begin at 2.5 mg once weekly (a sub-therapeutic initiation dose intended to improve gastrointestinal tolerability), increase to 5 mg once weekly after four weeks, then increase in increments of 2.5 mg no more frequently than every four weeks as tolerated, to a maintenance dose of 5, 10, or 15 mg once weekly [21]. The titration ladder is: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, each step separated by four weeks minimum [21].

In the SURPASS programme (type 2 diabetes), the three doses studied at maintenance were 5 mg, 10 mg, and 15 mg once weekly [3][5]. In the SURMOUNT programme (obesity), the same three doses were studied following the same 20-week stepwise escalation from 2.5 mg [5].

For the obesity indication, the approved dose range is the same: initiate at 2.5 mg, titrate as tolerated to a maximum of 15 mg once weekly [12].

Tirzepatide dose: what each maintenance dose measured in trials

In SURMOUNT-1 (the 72-week obesity trial in 2,539 adults without diabetes), mean weight changes at week 72 were [5]:

  • 5 mg: -15.0% versus -3.1% with placebo
  • 10 mg: -19.5% versus -3.1% with placebo
  • 15 mg: -20.9% versus -3.1% with placebo

In SURPASS-2 (the 40-week type 2 diabetes trial versus semaglutide 1 mg), HbA1c reductions were [3]:

  • 5 mg: -2.01 percentage points
  • 10 mg: -2.24 percentage points
  • 15 mg: -2.30 percentage points

Versus -1.86 percentage points with semaglutide 1 mg [3].

In SURMOUNT-5, maximum-tolerated-dose tirzepatide (10 or 15 mg) produced -20.2% weight change versus -13.7% with maximum-tolerated-dose semaglutide over 72 weeks [6].

A post-hoc SURPASS pooled analysis found early glycaemic response at week 4 (≥20% fasting serum glucose reduction) predicted better long-term outcomes, but non-early responders still achieved clinically meaningful HbA1c and weight reductions at all doses [10].

Tirzepatide injection: route, site, and formulation

The tirzepatide injection route studied in all approved clinical trials and the approved formulation is subcutaneous — administered under the skin, most commonly in the abdomen, thigh, or upper arm. Intravenous and oral routes have not been part of the approved programme; subcutaneous is the only documented route [21].

Marketed formulations are refrigerated single-dose injection pens and vials; the clinical trial product was a subcutaneous solution. Specific reconstitution and storage parameters are formulation-dependent and outside the scope of the published efficacy literature.

The FDA label advises rotating injection sites to reduce injection-site reactions, which are the second most frequently reported category in FAERS post-market data — accounting for over 19,000 reports from 2022 to early 2025 [21][33].

Perioperative considerations apply because tirzepatide's slowed gastric emptying may leave retained gastric contents at endoscopy or general anaesthesia. Reviewers have proposed prolonged pre-procedural fasting, point-of-care gastric ultrasound, or prokinetics around procedures [27][28].

Half-life and pharmacokinetics

The elimination half-life of tirzepatide is approximately five days [1]. This long half-life is conferred by the C20 fatty-diacid (eicosanedioic acid) moiety attached to the lysine side chain of the 39-amino-acid peptide backbone, which binds tightly to serum albumin and slows renal clearance and proteolytic degradation [1]. The albumin-binding mechanism is the same approach used for long-acting fatty-acid-acylated incretin analogues, adapted for dual-receptor engagement.

The five-day half-life supports once-weekly dosing: with a once-weekly injection, tirzepatide reaches steady-state plasma concentrations within 4–8 weeks in the escalation phase [21]. The molecule is dosed sub-therapeutically at 2.5 mg for the first four weeks specifically to limit the GI-intolerance burden during the period when plasma concentrations are rising toward the therapeutic window.

A phase 1 study (Urva et al., Diabetes Obes Metab 2020) found tirzepatide transiently delays gastric emptying to a degree similar to selective long-acting GLP-1 receptor agonists, an effect that attenuates with continued dosing — pharmacokinetically consistent with the five-day half-life and the time-course of GI adverse events [28].